The benefits of Vitamin D during pregnancy to the child often fade by age 5

How Long Do the Child's Benefits From Good Vitamin D Levels in Pregnancy Last? The Evidence by Outcome

Claude AI - Research mode

For bone and tooth enamel, randomized trials show benefits still present at age 6–7, and one post hoc trial analysis found better memory at age 10. So "5 years" is not a ceiling for those outcomes. For asthma and wheeze, the early benefit fades by school age. For the outcomes people care about most over the long term (adult peak bone mass, multiple sclerosis, schizophrenia, type 1 diabetes), there are no randomized trials. Only observational data exist, and they reach ages 20–40.

TL;DR

The effects that last are skeletal and dental, and they are measured, not assumed. In MAVIDOS (1000 IU/day), children's bone density was higher at age 4 and again at age 6–7, with no sign of shrinking. In COPSAC2010 (2800 IU/day total), bone mineral was higher at age 6 and enamel defects were about halved. COPSAC2010 is also the only trial to reach age 10: the post hoc analysis found better verbal and visual memory, but no effect on IQ, autism or ADHD.
Asthma and wheeze benefits fade. VDAART and COPSAC2010 each showed a 20–25% lower risk of asthma or recurrent wheeze by age 3. This reached statistical significance only in the pooled 2017 PLOS One analysis (aOR 0.74, 0.57–0.96). By age 6, neither trial showed any effect. The benefit reappears only in post hoc subgroups defined by the mother's baseline vitamin D level or genotype.
The decades-long claims rest on observational data. In the Raine cohort, maternal deficiency was linked to 2.7% lower bone mineral content at age 20. In Finnish and Danish biobank studies, low maternal or newborn vitamin D was linked to higher adult risk of MS and schizophrenia. But results for type 1 diabetes and one large Finnish schizophrenia study are null, and no trial has followed children past age 10.

Key Findings

Short answer to "5 years?": Benefits do not simply switch off at 5, but what happens depends on the outcome:

Persists past 5 years (RCT evidence): bone mineral density or content (to age 6–7) and enamel defects (to age 6).[1]
Appears later (RCT evidence, weaker): memory at age 10 (post hoc).[2]
Fades (RCT evidence): asthma or recurrent wheeze (gone by age 6).[3]
Null in RCTs: autism and ADHD at age 10, and bone in Bangladesh at age 4.[4]
Unknown or observational only: adult peak bone mass, MS, schizophrenia and type 1 diabetes.

The trials stop at age 10. The longest randomized follow-up of any pregnancy vitamin D trial is COPSAC2010 at age 10. Anything claimed about adolescence or adulthood is observational: it shows correlation, may be confounded, and usually rests on a single blood sample.

Doses that raise maternal 25(OH)D to about 27–43 ng/mL (67–108 nmol/L) are the ones with measurable child effects. Achieved late-pregnancy levels in the three key trials:

COPSAC2010: 108 vs 72 nmol/L (43 vs 29 ng/mL).[5]
VDAART: 39 vs 27 ng/mL (98 vs 67 nmol/L).[6]
MAVIDOS: 67.7 vs 43.1 nmol/L (27 vs 17 ng/mL).[7]

Most trials started in the second or third trimester, so none tested supplementation from conception.[3]

Summary Table: Outcomes vs. Longest Follow-up

Outcome	Longest RCT follow-up	RCT result at that age	Longest observational follow-up	Bottom line
Bone mineral density/content	Age 6–7 (MAVIDOS); age 6 (COPSAC2010)	Higher by 0.15–0.20 SD; persists	Age 20 (Raine)	Persists beyond 5 y; adult effect observational only
Bone (low-income setting)	Age 4 (MDIG, Bangladesh)	No effect	—	Null; setting-dependent
Fractures	Age 6 (COPSAC2010)	Fewer fractures, mainly combined with childhood sufficiency	Not reported	Suggestive; secondary analysis
Dental enamel defects	Age 6 (COPSAC2010)	OR 0.47–0.50 (about 50% fewer)	Not reported	Persists to 6 y; no caries effect
Asthma/recurrent wheeze	Age 6 (VDAART; COPSAC2010)	Null at 6 y (early effect faded)	Age 10 (Aberdeen, intake-based)	Fades by school age
Lung function	Age 6–8 (VDAART; COPSAC2010)	No spirometry effect in ITT	Age 6 (VDAART observational)	Unproven
Memory/cognition	Age 10 (COPSAC2010)	Verbal +0.17 SD; visual +0.24 SD; IQ unchanged	Not reported	Emerging; post hoc
Autism	Age 10 (COPSAC2010)	Null, OR 0.72 (0.21–2.29)	Childhood-adolescence (Finnish; Generation R)	RCT null; underpowered
ADHD	Age 10 (COPSAC2010)	Null, OR 0.87 (0.50–1.51)	Childhood (Finnish, 1067 cases)	RCT null; cohorts positive
Multiple sclerosis	None	—	Young adulthood (Finnish Maternity Cohort)	Observational only
Schizophrenia	None	—	Adulthood (Danish neonatal; Finnish maternal)	Conflicting observational
Type 1 diabetes	None	—	Age 15 (Norway; DNBC + MoBa)	Mostly null

Details

Randomized controlled trials

COPSAC2010 (Denmark) is the longest-running trial:

Design: 623 women were randomized at week 24 to 2400 IU/day vitamin D3 or placebo, taken until 1 week postpartum. Both arms also took 400 IU/day, so the comparison is 2800 vs 400 IU/day.[5][8]
Blood levels: in the 496 children analyzed at age 10, mothers' post-intervention 25(OH)D was 108 vs 72 nmol/L (43 vs 29 ng/mL). Pre-intervention levels were already about 76 nmol/L in both arms, so this was a well-nourished population.[5]
Wheeze and asthma: persistent wheeze by age 3 had HR 0.76 (0.52–1.12), not significant. At age 6, 545 of 581 children (94%) were followed; asthma was diagnosed in 23 of 274 (8%) in the high-dose group, with no difference between groups.[9]
Bone: there was no DXA difference at age 3. At age 6, whole-body bone mineral content and density were higher in the high-dose group (n=383, about 0.15–0.2 SD).[1] A follow-up paper reported fewer fractures when high-dose prenatal vitamin D was combined with vitamin D sufficiency in childhood.[1][10][11][12]
Teeth: enamel defects at age 6 were 8.6% vs 15.9% in baby teeth (OR 0.50, 0.28–0.87) and OR 0.47 (0.27–0.81) in permanent molars. There was no effect on caries.[8]
Autism and ADHD at age 10: no effect.
- Autism OR 0.72 (0.21–2.29), 5 vs 7 cases.[5]
- ADHD OR 0.87 (0.50–1.51), 27 vs 31 cases.[5]
Observational signal within the same cohort: mothers' pre-intervention 25(OH)D was associated with lower risk. Per 10 nmol/L, autism OR was 0.76 and ADHD OR 0.88.[13]
Cognition at age 10: a post hoc analysis published in JAMA Network Open in May 2026 (n=498) found higher verbal memory (+0.17 SD) and visual memory (+0.24 SD). Estimated IQ was the same (107.6 vs 107.8), and a set-shifting benefit did not survive correction for false discovery rate.[2][14]

VDAART (USA) enrolled women at high risk of having a child with asthma:

Design: 876 women were randomized at 10–18 weeks to 4000 IU/day plus 400 IU/day, or to 400 IU/day alone.[15][16][17][18]
Blood levels: third-trimester 25(OH)D was 39 vs 27 ng/mL.[6]
By age 3: asthma or recurrent wheeze occurred in 24.3% vs 30.4%, HR 0.8 (0.6–1.0), P=0.051.[19]
By age 6: 43.5% vs 45.9%, a non-significant HR (P=0.25). There was no effect on spirometry and only a small airway-resistance difference of uncertain significance. The NEJM paper "Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction" (2020) concluded that prenatal supplementation "alone did not influence the 6-year incidence of asthma and recurrent wheeze among children who were at risk for asthma."
Later post hoc work: the investigators' 15-year review reports significant reductions at ages 3 and 6 in analyses stratified by baseline 25(OH)D and genotype, and recommends 4400 IU/day.[20][21] These are the investigators' own secondary analyses and should be weighed as such.[22][23]

The combined COPSAC2010 + VDAART analysis pooled 1387 women. It found a 25% reduction in asthma or recurrent wheeze by age 0–3 (aOR 0.74, 0.57–0.96, P=0.02). The effect was largest when the mother's 25(OH)D at entry was at least 30 ng/mL (aOR 0.54, 0.33–0.88) and absent when it was below 30 ng/mL (aOR 0.84, 0.62–1.15). This fits the idea that the benefit depends on status early in pregnancy, before randomization.

Genotype also appears to matter:

A VDR genotype subgroup effect in COPSAC2010 did not replicate in VDAART.[24]
The mother's 17q21 genotype modified the effect in the combined data.[25][26]

A pooled pharmacokinetic analysis extended lung function measurements to age 8.[16][27]

MAVIDOS (UK) tested a modest dose:

Design: 1134 women with baseline 25(OH)D of 25–100 nmol/L took 1000 IU/day or placebo from 14–17 weeks.[28][29][30]
Blood levels: at 34 weeks, 67.7 vs 43.1 nmol/L.[7]
Newborns: bone mass was not higher overall, but was higher in winter-born babies (a prespecified subgroup).[31]
Age 4: whole-body-less-head areal BMD was 0.477 vs 0.470 g/cm² (P=0.048, n=452).[31]
Age 6–7 (n=447): BMC +0.15 SD (0.04–0.26), BMD +0.18 SD (0.06–0.31) and lean mass +0.09 SD. The effect was "similar at ages 4 and 6–7 y," so it held steady rather than fading.[32]
Caveats: only Southampton children were followed, and the authors call the age 6–7 analysis exploratory and post hoc.[4][33]

MDIG (Bangladesh, Roth et al.) found nothing:

Design: 1300 women were randomized at 17–24 weeks to placebo or 4200, 16,800 or 28,000 IU/week, some continuing to 26 weeks postpartum.[34]
Results: no effect on infant growth at 1 year, and no difference in bone mass at age 4 (n=642).[4][35]
Why it matters: background malnutrition and calcium deficiency may blunt skeletal effects, so the bone benefit seen in Europe may not generalize.[4]

Hollis and Wagner trials (Charleston, 400, 2000 or 4000 IU/day from 12–16 weeks) looked at development at age 3–5. The child's own 25(OH)D at the time of testing was associated with better Brigance screening scores.[36] That points to an effect of current vitamin D status, not a lasting effect of what happened in pregnancy.

Cochrane (Palacios 2024) is uninformative on long-term child outcomes. It removed 21 studies after trustworthiness screening and concluded that the evidence on core pregnancy outcomes is very uncertain.[37][38]

Prospective observational cohorts

Bone:

The Raine Study (Zhu et al., J Bone Miner Res 2014, n=341) links pregnancy status to adult bone. Mothers' 25(OH)D at 18 weeks averaged 57.2 nmol/L (23 ng/mL), and 38.7% were below 50 nmol/L. Children of deficient mothers had 2.7% lower total-body BMC and 1.7% lower BMD at age 20.[39]
ALSPAC (UK) found no association with bone mass at age 9–10, and Generation R (Rotterdam) was also null.[28][40]
Adult bone benefit is therefore plausible but not consistent across cohorts.

Respiratory:

In COPSAC2000, cord-blood 25(OH)D below 50 nmol/L was linked to recurrent troublesome lung symptoms up to age 7 (HR 2.65), but not to asthma, lung function or eczema.[41]
The Aberdeen cohort linked pregnancy vitamin D intake to asthma at age 10. That study measured intake, not blood levels.[42]

Neurodevelopment and psychiatric outcomes:

Finnish biobank studies (1067 ADHD cases) show inverse associations between maternal 25(OH)D and ADHD.[43]
For autism, a Finnish study found an association, while a large Southern California study was null.[44]
A dose-response meta-analysis of 10 studies (Tirani et al., Psychiatry Research 2022) found that each 25 nmol/L (10 ng/mL) of maternal 25(OH)D was associated with lower risk of autism (OR 0.81, 0.76–0.87) and ADHD (RR 0.82, 0.73–0.92).
For schizophrenia, Danish newborn blood spots (Eyles et al., Scientific Reports 2018, n=2602) linked neonatal deficiency (lowest quintile, below 20.4 nmol/L) to 44% higher adult risk (IRR 1.44, 1.12–1.85). But a Finnish study of 1145 cases (Sourander et al., Schizophrenia Research 2024, Finnish Prenatal Study of Schizophrenia) found no association with maternal 25(OH)D (aOR 0.98, 0.79–1.22).
A 2025 Danish case-cohort study in Lancet Psychiatry ("Convergent evidence linking neonatal vitamin D status and risk of neurodevelopmental disorders") added genetic (Mendelian randomization) support for a causal link between neonatal vitamin D and ADHD.

Autoimmune disease:

Multiple sclerosis: in the Finnish Maternity Cohort (Munger et al., JAMA Neurology 2016, 193 cases), maternal deficiency in early pregnancy (below 12 ng/mL) was associated with higher MS risk (RR 1.90, 1.20–3.01). Mean maternal levels were only 13.9 ng/mL in mothers of cases and 15.0 ng/mL in mothers of controls, and cases were diagnosed at about age 20–27.
Type 1 diabetes: an early Norwegian study was positive. The larger Scandinavian case-cohort (DNBC + MoBa) found no association with either maternal or newborn vitamin D.[45][46]

Can vitamin D given to the child after birth explain "persistence"?

Yes, in part, and this matters for interpreting every long-term result:

Danish and UK infants routinely receive 400 IU/day.
The COPSAC2010 fracture benefit appeared mainly when the child was also sufficient.[12]
MAVIDOS adjusted its age 6–7 results for current vitamin D use and the effect remained.[47][48] This is the strongest evidence that the effect comes from pregnancy itself.
In the Charleston follow-up, the child's current level, not prenatal allocation, predicted development.[36]
Cohort studies rarely separate prenatal status from the child's later status. Raine data show that vitamin D status tracks from childhood into adulthood.[49]

Recommendations

Recommended VitaminDWiki framing: "Benefits for bone and teeth are proven by randomized trials to at least age 6–7, and memory benefits have been reported at age 10. Asthma benefit fades by age 6 unless the mother started pregnancy with good levels. Lifelong benefits (MS, schizophrenia, adult bone) are suggested by observational studies only."
Timing: start before conception or in the first trimester. The trials that began at weeks 10–26 likely missed early windows of lung and brain development,[3] and the asthma benefit concentrated in mothers who were already at or above 30 ng/mL at entry.[50][51]
Target: aim for maternal 25(OH)D of at least 30–40 ng/mL (75–100 nmol/L). The effective trial arms reached 27–43 ng/mL.
Childhood: continue the child's own vitamin D supplementation. It likely adds to the prenatal effect, and the trials cannot cleanly separate the two.
What to watch for: MAVIDOS peripheral quantitative CT results at age 6–7,[1] any COPSAC2010 or VDAART follow-up into adolescence, and the new 4000-woman COPSAC vitamin D/fish oil trial.[1][52]

Caveats

Many of the positive long-term results are secondary or post hoc analyses: MAVIDOS at 6–7, COPSAC2010 bone and teeth, and cognition at age 10. They were not the trials' primary outcomes.
Trial populations were mostly replete at baseline (COPSAC2010 about 76 nmol/L), which biases trials toward null results. Deficient populations, where benefit should be largest, are underrepresented except in MDIG, which was null.
Bone density measured by DXA is a surrogate endpoint. No trial has yet shown fewer adult fractures.
Observational MS and schizophrenia findings rely on one maternal or newborn sample, may be confounded by season and socioeconomic status, and conflict with null studies. The VDAART investigators' recommendation of 4400 IU/day comes from their own post hoc analyses.

Sources

Related in VitaminDWiki

Bone gains from 2800 IU of vitamin D in pregnancy had faded by age 13 - RCT